Posts

Alexion has boosted AstraZeneca’s rare disease expertise while the company has experienced success in oncology and COVID-19.

Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.

The French drugmaker is in talks with a potential partner on producing an updated version of its COVID-19 vaccine that targets new variants of the disease, sending its shares up. Valneva has struggled to bring its COVID-19 vaccine to market to compete with rival products from drugmakers such as AstraZeneca, Moderna and BioNTech/Pfizer.

AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday.

The U.S. Food and Drug Administration’s (FDA) staff on Tuesday raised concerns over the safety of Spectrum Pharmaceutical’s experimental cancer drug and questioned the benefits it provided over existing therapies, dragging its shares 30%.

Europe’s medicines regulator has backed using AstraZeneca’s preventative COVID-19 therapy as a treatment for the disease and also endorsed another medicine as preventative option for another common virus.

AstraZeneca said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.

AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.

Biogen announced that its mid-stage monoclonal antibody, litifilimab, is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.

Gilead Sciences Inc.’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ahead of a presentation at a European cancer meeting on Friday.